Nellix内血管动脉瘤封闭系统长期随访中的器械失败进展
该回顾性研究纳入161例接受Nellix EVAS的患者,中位随访6.0年。6年全因死亡率无事件估计为41.5%,器械失败70例(43.5%),6年无器械失败估计为32.3%。失败原因包括囊扩张、支架迁移、支架分离和继发性AAA破裂,再干预36例(22.4%),开放取出21例无30天死亡。
要点
- Nellix EVAS长期器械失败率高,6年无失败率仅32.3%。
- 所有植入Nellix患者需告知并纳入加强监测。
- 开放取出是可行技术且结果良好,适合患者应早期考虑。
核心结论
- Nellix EVAS长期器械失败率高,6年无器械失败估计为32.3%。
研究设计与样本
- 回顾性综述三级单位EVAS手术,纳入161例患者(男140,女21),中位随访6.0年(IQR 5.0-6.6)。
主要发现
- 6年全因死亡率无事件估计为41.5%,器械失败70例(43.5%)。
- 失败原因包括囊扩张41例、支架尾侧迁移36例、支架分离26例、继发性AAA破裂15例。
- 1a型内漏33例,1b型内漏11例,2型内漏率低为3.7%。
- 36例(22.4%)需再干预,21例开放取出无30天死亡。
- 6例Nellix-in-Nellix应用(NINA)中1例早期死于肠缺血,1例后期死于非动脉瘤相关原因。
关键数值与推荐
- 器械失败定义为支架迁移、支架分离和继发性囊扩张三联征,或任何因1型内漏、器械破裂或取出的干预。
临床怎么用
- 所有Nellix患者应被告知并纳入加强监测。
- 适合患者应早期考虑开放取出,并提供给器械失败者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: High rates of midterm failure of the Nellix EndoVascular Aneurysm Sealing (EVAS) System resulted in device withdrawal from the UK market. The study aim was to report long term Nellix EVAS outcomes and management of a failing device. METHODS: A retrospective review of EVAS procedures at a tertiary unit was performed. Device failure was defined as a triad of stent migration, stent separation, and secondary sac expansion, or any intervention for type 1 endoleak, device rupture, or explant. RESULTS: 161 (male n = 140, female n = 21) patients with a median follow up of 6.0 (IQR 5.0-6.6) years were included. Freedom from all cause mortality estimate at six years was 41.5%. There were 70 (43.5%) device failures with a freedom from device failure estimate at six years of 32.3%. Failure was the result of sac expansion (n = 41), caudal stent migration (n = 36), stent separation (n = 26), and secondary AAA rupture (n = 15). A substantial number of type 1 endoleaks was present (1a n = 33, 1b n = 11), but the type 2 endoleak rate was low at 3.7%. Some 36 (22.4%) patients required re-intervention. Twenty-one patients underwent explant with no 30 day deaths. Six patients underwent Nellix-in-Nellix application (NINA) with one early death from bowel ischaemia and one patient who died later from non-aneurysm related cause. Two NINA patients have ongoing sac expansion and two have had thrombosis of a Nellix limb or visceral stent. Proximal embolisation was only successful in one of six cases. CONCLUSION: The long term failure rate of Nellix EVAS is high. All patients with a device must be informed and be enrolled in enhanced surveillance. EVAS explant is an acceptable technique with favourable outcomes. Management by open explant, if the patient is fit, should be considered early and offered to those with device failure.
引用
- Singh AA, Benaragama KS, Pope T, et al. Progressive Device Failure at Long Term Follow Up of the Nellix EndoVascular Aneurysm Sealing (EVAS) System. Eur J Vasc Endovasc Surg. 2020. PMID: 33303312. doi:10.1016/j.ejvs.2020.11.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。